Is bluebird bio One Step Closer to Its First Commercial Drug?

Beta thalassemia patients endure a lifetime of blood transfusions that can cause iron overload and life-threatening organ damage, but a new gene therapy developed by bluebird bio (NASDAQ: BLUE)may be about to change that. On Thursday, bluebird bio unveiled intriguing interim results from trials evaluating its beta thalassemia therapy, LentiGlobin, and so far, those results suggest that LentiGlobin could significantly reduce the need for blood transfusions.